Ozempic (semaglutide) reduces the risk of heart attack, stroke, and cardiovascular death by about 20% in people with established heart disease who are overweight or obese. That benefit comes from multiple overlapping effects: lower inflammation, improved blood pressure, better cholesterol levels, and direct actions on blood vessel walls. In March 2024, the FDA approved semaglutide as the first treatment specifically indicated to reduce serious cardiovascular events in adults with obesity or overweight and existing cardiovascular disease.
Direct Effects on Blood Vessels
Your heart and blood vessels have receptors for the hormone that semaglutide mimics (GLP-1). These receptors sit on heart muscle cells, the inner lining of blood vessels, and the smooth muscle wrapped around arteries. When semaglutide activates these receptors, it triggers the release of nitric oxide, a molecule that relaxes artery walls and improves blood flow. This vasodilation isn’t just theoretical. In lab studies, arteries physically widened in response to the drug, and blocking nitric oxide production eliminated the effect entirely.
This relaxation of blood vessels has a measurable impact on blood pressure. Across clinical trials, semaglutide lowered systolic blood pressure (the top number) by about 5 mmHg compared to placebo. That may sound modest, but sustained reductions of that size translate to meaningfully lower rates of stroke and heart attack over time, especially for people already at elevated risk. The benefit held across different levels of hypertension severity.
Reducing Inflammation That Damages Arteries
Chronic, low-grade inflammation is one of the key drivers behind clogged arteries. It damages the inner lining of blood vessels, making it easier for cholesterol to build up into plaques. Semaglutide directly lowers several markers of this kind of systemic inflammation.
The most well-studied marker is C-reactive protein (CRP), a blood test doctors use to gauge cardiovascular risk. In one controlled trial, 32 weeks of semaglutide treatment cut CRP levels by roughly 48%. That reduction remained significant even after adjusting for differences in age, sex, and smoking between study groups. Semaglutide also lowered interleukin-6, another inflammatory signal linked to heart disease progression. Animal studies suggest these anti-inflammatory effects occur independently of weight loss and blood sugar control, pointing to a direct protective action on artery walls.
Improvements in Cholesterol and Triglycerides
Semaglutide shifts your lipid profile in a favorable direction. A meta-analysis of randomized trials in overweight and obese adults without diabetes found that the drug significantly reduced total cholesterol by about 6.4 mg/dL, LDL (“bad”) cholesterol by about 6 mg/dL, and triglycerides by roughly 15 mg/dL. VLDL cholesterol, a particularly harmful type that carries fat through the bloodstream, dropped by nearly 11 mg/dL. None of these changes are dramatic on their own, but combined with the blood pressure and inflammation benefits, they contribute to a meaningful overall reduction in cardiovascular risk.
What the Major Trials Found
Two landmark trials established semaglutide’s heart benefits in different populations. The SUSTAIN-6 trial enrolled people with type 2 diabetes and high cardiovascular risk. Semaglutide reduced major adverse cardiovascular events (a composite of heart attack, stroke, and cardiovascular death) by 24% compared to placebo. The largest effect was on stroke: a 35% reduction. Heart attacks and cardiovascular deaths also declined, though by smaller margins.
The SELECT trial then tested whether these benefits extended to people without diabetes. It enrolled over 17,000 adults who were overweight or obese and had established cardiovascular disease but no diabetes. Over an average of 33 months, semaglutide reduced major cardiovascular events by 20%. The rate dropped from 8.0% in the placebo group to 6.5% in the treatment group. This trial was the basis for the FDA’s 2024 expanded approval, making semaglutide the first drug approved to reduce heart risk specifically in people with obesity or overweight.
Benefits for Heart Failure
Semaglutide also helps a specific type of heart failure called HFpEF, where the heart pumps normally but is too stiff to fill properly. This condition is closely linked to obesity, and there have historically been few effective treatments for it. The STEP-HFpEF trial showed that semaglutide improved patients’ symptom scores by 5 to 11 points on a standardized quality-of-life scale, depending on how symptomatic they were at the start. People who were most limited at baseline saw the greatest improvement.
Patients on semaglutide also walked farther on six-minute walk tests, a standard measure of functional capacity. The drug reduced both CRP and a hormone called NT-proBNP, which the heart releases when it’s under strain. Lower NT-proBNP suggests the heart is working under less pressure, not just that patients feel better subjectively.
One Trade-Off: A Slight Increase in Heart Rate
Semaglutide does raise resting heart rate by a small amount, averaging about 2.4 beats per minute across cardiovascular trials. During continuous monitoring, increases of 6 to 10 beats per minute have been reported in some individuals. This happens because the drug acts directly on the heart’s natural pacemaker cells. While a sustained resting heart rate increase of 5 beats per minute has been associated with a 17% increase in cardiovascular mortality in population studies, the overall trial data clearly show net cardiovascular benefit. Still, it’s worth knowing about if you already have a fast resting heart rate or a condition where heart rate matters.
How These Effects Work Together
No single mechanism explains semaglutide’s heart protection. The drug relaxes blood vessels, lowers blood pressure, reduces the inflammation that destabilizes artery plaques, improves cholesterol, and causes significant weight loss, which itself reduces strain on the heart. Importantly, animal research and the SELECT trial both suggest the cardiovascular benefits go beyond what weight loss alone would explain. People in these studies saw heart protection even when controlling for how much weight they lost, which means the drug appears to have direct protective effects on the cardiovascular system itself.
For someone already living with heart disease and carrying extra weight, this combination of effects targets several of the pathways that lead to heart attacks and strokes simultaneously, rather than addressing just one risk factor at a time.